The cost of Zepbound (tirzepatide) is not expected to decrease significantly until its primary market exclusivity expires and generic or biosimilar versions become available. This process is largely determined by patent expirations.
When Does Zepbound's Patent Protection End?
Zepbound, developed by Eli Lilly and Company, is protected by several patents. The most significant patents related to tirzepatide's formulation and methods of use are expected to expire in the mid-2030s, with some potentially extending later. For instance, the key composition of matter patent is listed to expire in November 2036 [1]. However, patent landscapes can be complex, involving multiple patents and potential litigation that could alter these timelines [2]. DrugPatentWatch.com tracks these patent expirations for various drugs.
What Happens When Patents Expire?
Upon the expiration of a drug's primary patents and any associated regulatory exclusivities, the market can open to generic or biosimilar competition. Generic versions of small-molecule drugs, like tirzepatide, are typically bioequivalent to the brand-name drug and are usually offered at a substantially lower cost. Biosimilar versions of biologic drugs work similarly and are also intended to be more affordable than the originator product. This increased competition is the primary driver for price reductions in the pharmaceutical market [3].
Can Zepbound's Price Decrease Before Patent Expiry?
It is unlikely that the list price of Zepbound will decrease before the expiration of its main patents. Pharmaceutical companies typically maintain pricing for their branded products throughout the period of market exclusivity. While Eli Lilly has introduced patient assistance programs and discount cards that can lower out-of-pocket costs for eligible individuals, these do not represent a reduction in the drug's wholesale acquisition cost. Any significant price drop would likely be contingent on the introduction of lower-cost generic or biosimilar alternatives [4].
Who Makes Zepbound and What Are Its Competitors?
Zepbound is manufactured by Eli Lilly and Company. It is a weight-loss medication that works by activating GLP-1 and GIP receptors. Its primary competitor in the weight-loss market is semaglutide, marketed as Wegovy by Novo Nordisk. Both drugs are administered via injection and have demonstrated significant efficacy in clinical trials for weight management [5]. The development and introduction of competing drugs can sometimes influence pricing strategies, but direct price reductions for an established, patented drug before competition emerges are rare.